STARD4 impairs the anti-tumor effect of lenvatinib. (IMAGE)
Caption
(A, B) The cell viability of STARD4-silencing and STARD4-overexpressing hepatocellular carcinoma cells treated with different concentrations of lenvatinib for 48 h was detected by CCK8 assay. (C) The mRNA expression of STARD4 in hepatocellular carcinoma cells treated with lenvatinib was detected by quantitative reverse transcription PCR. (D, E) The migration and invasion of hepatocellular carcinoma cells with STARD4 silencing or overexpressing after exposure to lenvatinib (10 μM) were examined by wound healing assay and transwell assay. The data were shown as mean ± standard deviation (n = 3). *P < 0.05, **P < 0.01, and ***P < 0.001 versus the corresponding control.
Credit
Mengting Liu, Yixin Liu, Jiahui Zheng, Xiangping An, Jiayong Wen, Fengchi Zhu, Jin Jia, Dan Guo, Nana Chen
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND